Zura Bio LTD 10-Q quarterly reports

Zura Bio Limited reported a net loss of $26.3 million for Q2 2026, with increased R&D expenses, while maintaining a substantial cash balance of $205.1 million.

Zura Bio reports a significant increase in R&D expenses for Q1 2026, driven by ongoing clinical trials, while maintaining a robust cash position following a recent equity offering.

Zura Bio Limited reported increased R&D expenses for its lead product candidates and a higher net loss for the nine months ended September 30, 2025, while maintaining liquidity through 2027.

Zura Bio Limited reported a significant increase in net losses for the second quarter and first half of 2025, driven by higher research and development and general and administrative expenses, while advancing its lead product candidates into Phase 2 clinical trials.

Zura Bio Limited reports a net loss for Q1 2025 while advancing its clinical-stage product candidates and evaluating development opportunities.

Zura Bio Limited released its third quarter 2024 financial results, showcasing advancements in its clinical programs and a strengthened financial position.

Zura Bio Limited, a clinical-stage biotechnology company, released its financial results for the second quarter of 2024, highlighting a decrease in research and development expenses and a recent warrant exchange.

Zura Bio Limited has filed an amendment to its quarterly report on Form 10-Q for the period ended March 31, 2024, solely to correct the number of outstanding Class A ordinary shares.

Zura Bio Limited, a clinical-stage biotechnology company, released its first quarter 2024 financial results, showing a net loss of $7.7 million and highlighting ongoing research and development activities.